Neogenix Oncology Inc
Healthcare · In Vitro & In Vivo Diagnostic Substances · MD · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY11 | FY10 | |
|---|---|---|
| Revenue | — | — |
| Operating income | −$117.0M | −$19.6M |
| Net income | −$115.5M | −$19.1M |
| Total assets | $6.3M | $12.9M |
| Total liabilities | $2.3M | $1.6M |
| Equity | $4.0M | $11.3M |
| EPS (diluted) | — | — |
| Shares out. | — | — |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2011- Operating margin
- —
- Net margin
- —
- Return on equity
- −2887.0%
- Return on assets
- −1821.1%
- Return on capital (ROCE)
- −2305.2%
- Liabilities / assets
- 36.9%
- Debt / equity
- 0.59×
- Book value / share
- —
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2011- Accruals / assets
- −1094.7%clean
- Piotroski F-Score
- 1/6weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 1 warning● 2 good- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Mar 30, 2012
- NT 10-Qmissed a reporting deadline ↗Nov 15, 2011
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Completed an acquisition or dispositionSep 28, 2012
- Entered a material agreementSep 7, 2012
- Entered a material agreement · Bankruptcy or receivership · Other material eventJul 26, 2012
- Director / officer changeJul 6, 2012
- Other material eventJul 3, 2012
- Other material eventMar 6, 2012
- Director / officer change · Other material eventFeb 6, 2012
- Other material eventJan 12, 2012
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- REVOKEDAug 26, 2019
- 4OWNERSHIP DOCUMENTFeb 13, 2013
- 4OWNERSHIP DOCUMENTFeb 13, 2013
- 4OWNERSHIP DOCUMENTFeb 13, 2013
- 8-KCURRENT REPORTSep 28, 2012
- 8-KCURRENT REPORTSep 7, 2012
- 8-KFORM 8-KJul 26, 2012
- 10-KFORM 10-KJul 12, 2012
- 8-KCURRENT REPORTJul 6, 2012
- 8-KFORM 8-KJul 3, 2012
- NTN 10QNT 10-QJun 5, 2012
- 10-QFORM 10-QApr 23, 2012
- NT 10-KNOTIFICATION OF LATE FILINGMar 30, 2012
- 8-KCURRENT REPORTMar 6, 2012
- 8-KCURRENT REPORTFeb 6, 2012
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.